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http://dx.doi.org/10.1016/j.jfma.201Human cytomegalovirus (HCMV) is a large DNA virus and a member of the betaherpesvirus
family. HCMV infection is extremely common in human populations and can cause severe
diseases in immunocompromised hosts. Ganciclovir is the most widely used antiviral drug for
cytomegalovirus infection and works by blocking the amplification of HCMV. HCMV strains resis-
tant to ganciclovir have been detected in recent decades and mainly result from mutations in
UL97 (protein kinase) and UL54 (DNA polymerase) genes. In order to understand the prevalence
of resistance of HCMV in Taiwan, we studied 40 clinical isolates to detect the mutations of
UL97 and UL54 that might be related to resistance. The results showed that no mutation known
to cause ganciclovir resistance was detected in any strain, but some polymorphisms (N685S,
A688V, A885T, N898D in UL54; D605E in UL97) were frequently observed. Our results suggest
that resistant HCMV strains are not prevalent in Taiwan.
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1.08.025Introduction
Human cytomegalovirus (HCMV) is a ubiquitous virus and
infects the great majority of humans early in their lives.1
Being a human herpesvirus, HCMV is capable of establish-
ing life-long latency after primary infection.1,2 Reactivation& Formosan Medical Association. All rights reserved.
Resistance-associated mutations in Cytomegalovirus 457of HCMV is not a rare event in the lifetime of infected
individuals. HCMV infection is a particular problem among
immunocompromised patients, such as those with AIDS,
recipients of bone marrow and organ transplants, and those
receiving immunosuppressive or chemotherapeutic
agents.3,4 Currently, three effective antiviral agents (gan-
ciclovir, foscarnet, and cidofovir) are available to suppress
HCMV replication, by suppressing DNA polymerase (pUL54)
activity.5,6 Ganciclovir has been widely used clinically for
HCMV infections.7 However, development of drug-
resistance in HCMV has been frequently observed and
becomes a clinical concern after long-term use of antiviral
treatment.8 Resistance of HCMV can be determined by
phenotype or genotype assay.9 Phenotype assay is
cumbersome whereas genotype assay is faster and easier to
perform. However, although genotype assay is often able to
assist prompt diagnosis, enabling treatment to be started
quickly, the mutations detected through genotype assay
may be hard to interpret. The mutations may be only
polymorphisms (sequence variants not reducing drug
susceptibility) or actual resistance-conferring mutations.
Only marker transfer experiments enable discrimination
between polymorphisms and resistance mutations.9,10
Ganciclovir is phosphorylated by CMV protein kinase
(pUL97) initially, and then undergoes two phosphorylation
steps by cellular kinase.5,6 Resistance of CMV to ganciclovir
comes from mutations in two viral genes, namely UL97 and
UL54. Mutations in the UL97 gene lead to loss of the phos-
phorylation function of the UL97 gene product, thus
impairing the first step of ganciclovir phosphorylation.9,10
Ganciclovir, foscarnet, and cidofovir exert antiviral
effects through suppression of HCMV DNA polymerase
function; hence, mutations in the DNA polymerase gene
(UL54) could result in resistance to all the three
agents.11e13 Antiviral therapy and prophylaxis against HCMV
infection has been used in Taiwan for decades but the
frequency of antiviral resistance among Taiwan HCMV
strains is unknown. This study aimed to understand the
mutations in UL97 and UL54 genes in HCMV strains circu-
lating in Taiwan.
Materials and methods
Virus and nucleic acid extraction
We collected 40 HCMV isolates from clinical specimens
using a human fibroblast cell line in the National Taiwan
University Hospital during 2009 and 2010. The complete
nucleic acid was extracted from the supernatant of the
virus-infected cell culture by MagNA Pure LC 2.0 (Roche
Diagnostics, German).
Genotypic analysis of the UL97 and UL54 genes
Amplification of antiviral resistance regions of UL97
(domains VI, VIII, and IX) and UL54 (domains IV to V)11,12
using nested polymerase chain reactions (nested-PCR),
which contained 35 cycles of denaturation for 40 seconds at
95 C, annealing for 40 seconds at 57.5 C, and elongation
for 75 seconds at 72 C. The first round primers for the
UL97 region (codons 382-614) were outer-UL97-F (5’-ggACATgAgCgACgAgAgCT-3’) and outer-UL97-R (5’-gTACgC-
gACACgAggACATC-3’) and second round primers were inner-
UL97-F (5’-ggTgCTCACggTCTggATgT-3’) and inner-UL97-R
(5’-AgACAggCgCCgTAgCTCAT-3’). For amplification of UL54
(codons 340-989), the first round primers of the front region
were outer-UL54-A-F (5’-ATCggCggATCACCACgTTC-3’) and
outer-UL54-A-R (5’-gTTCTCTAgCgTgACgCTgTAT-3’), and the
second round primers were inner-UL54-A-F (5’-ATTCA
gATCTCgTgCgTgTgCT-3’) and inner-UL54-A-R (5’-TgRgCCAT
gATgATggAAgg-3’). The first round primers of the rear
region of UL54 were outer-UL54-B-F (5’-CCAggTAggCCgT
TACTgTCT-3’) and outer-UL54-B-R (5’-ACACggTgCAggTA
CAgATCgT-3’), and the second round primers were inner-
UL54-B-F (5’-TggTgCgCgATCTgTTCAACAC-3’) and inner-
UL54-B-R (5’-gCTTCCgAgACCTCgCgATCCT-3’).
DNA sequencing and data analysis
PCR products were recovered by using a Gel/PCR DNA
fragments extraction kit (Geneaid, Taiwan), and
sequenced by automated DNA sequencing (ABI 3730). The
nucleotide acid sequences were compared with AD169
using EBI ClustalW2, version 2.0 (Cambridge, UK) and
GeneDoc, version 2.6, software (http://www.psc.edu/
biomed/genedoc).
Results
The HCMV were isolated from 40 clinical specimens, con-
sisting of 20 throat swabs, 7 blood samples, 5 sputa, 4
urine samples and 4 aqueous humors (Table 1). To be
representative, the HCMV clinical isolates were collected
from 25 inpatients and 15 outpatients. The inpatients had
been diagnosed with various diseases, and nine of these
patients were receiving ganciclovir following trans-
plantation or for serious HCMV infection. HCMV strains
were also isolated from 15 outpatients who had less severe
illnesses. The UL54 and UL97 genes were amplified and
sequenced. There were no known mutations conferring
ganciclovir resistance in either the inpatient or outpatient
isolates. However, we detected some common poly-
morphisms in local HCMV strains. The most common
polymorphism in UL97 was D605E, observed in 28 of the 40
(68%) isolates. Four known UL54 polymorphisms (N685S,
A688V, A885T, N898D)14 were also frequently detected in
29 of the 40 (73%) isolates.
Of the eight transplant recipients (patients 25, 28, 29,
30,31, 37, 38, and 40) from whom clinical isolates were
collected, four were receiving ganciclovir (patients 29,
31, 37, and 40). No distinct polymorphism was found in the
transplant recipients, except for four changes (K409 M,
T690A, S694A in UL54 and G391S in UL97) detected in
patients 28, 31, and 40. On the other hand, nine patients
received ganciclovir for serious HCMV infection (patients
27, 29, 31, 34, 35, 37, 38, 39, and 40), and seven of them
revealed unusual variations (see Table 1).
In order to assess whether the ganciclovir-resistant
strains were widespread, we collected 15 HCMV strains
from outpatients who were community dwellers without
obvious immune suppression. Thirteen of these outpatient
isolates (87%) had polymorphisms (see Table 1).
Table 1 Sequence polymorphism in antiviral regions of UL54 and UL97 compared with AD169 strain and the patient/specimen type and period of ganciclovir treatment.
Patient ID UL54 UL97 Ganciclovir
treatment
(days)
Sample
sourcee
Diagnosisf Specimen
typeg
Ganciclovir
resistanta
Polymorphismb Unknownc Ganciclovir
resistanta
Polymorphismd Unknownc
1 e N685S, A688 V, A885 T, N898D e e e e e O. C. Panuveitis aq. H
2 e N685S, A688 V, A885 T, N898D e e e e e O. C. Panuveitis aq. H
3 e N685S, A688 V, A885 T, N898D e e D605E e e O. C. Panuveitis aq. H
4 e N685S, A688 V, A885 T, N898D e e D605E e e O. C. Panuveitis aq. H
5 e N685S, A688 V, A885 T, N898D e e D605E e e O. C. URI TH
6 e N685S, A688 V, A885 T, N898D e e D605E e e O. C. URI TH
7 e N685S, A688 V, A885 T, N898D e e D605E e e O. C. URI TH
8 e N685S, A688 V, A885 T, N898D e e D605E e e O. C. URI TH
9 e N685S, A688 V, A885 T, N898D e e D605E e e O. C. Epilepsy, URI U
10 e N685S, A688 V, A885 T, N898D L957P e D605E e e O. C. Croup TH
11 e N685S, A885 T, G874R, N898D T690A e D605E e e O. C. Congenital CMV
infection
B
12 e S655L, N685S, G874R, A885 T, N898D e e D605E A590 V e O. C. Pneumonia U
13 e S655L, N685S, G874R, A885 T, N898D S646F, G678S e D605E e e O. C. Cholestasis in
newborn
TH
14 e S655L, A688 V, G874R, A885 T, N898D A472 T e D605E A477 V e O. C. AOM TH
15 e N685S, A688 V, G874R, A885 T, N898D e e D605E e e O. C. URI TH
16 e N685S, A688 V, A885 T, N898D e e e e e I. C. ALL, Klebsiella
pneumonia
Sp
17 e N685S, A688 V, A885 T, N898D e e e e e I. C. TOF, influenza TH
18 e N685S, A688 V, A885 T, N898D e e e e e I. C. TOF TH
19 e N685S, A688 V, A885 T, N898D e e e e e I. C. OHT/DCM B
20 e N685S, A688 V, A885 T, N898D e e D605E e e I. C. Bronchopneumonia TH
21 e N685S, A688 V, A885 T, N898D e e D605E e e I. C. Acute bronchiolitis TH
22 e N685S, A688 V, A885 T, N898D e e D605E e e I. C. AIDS, interstitial
pneumonitis
TH
23 e N685S, A688 V, A885 T, N898D e e D605E e e I. C. Acute bronchiolitis TH
24 e N685S, A688 V, A885 T, N898D e e D605E e e I. C. Multiple myeloma TH
25 e N685S, A688 V, A885 T, N898D e e D605E e e I. C. Liver transplantation/
chronic HCV infection
with liver cirrhosis
B
26 e N685S, A688 V, A885 T, N898D e e D605E e e I. C. Pneumonia TH
27 e N685S, A688 V, A885 T, N898D e e D605E e 42 I. C. Congenital CMV
infection
U
28 e N685S, A688 V, A885 T, N898D e e e G391S e I. C. PBSCT/ALL B
29 e N685S, A688 V, A885 T, N898D e e e L568 G 25 I. C. CBT/CMV
pneumonitis
Sp
30 e N685S, A688 V, G874R, A885 T, N898D e e D605E e e I. C. PBSCT/multiple
myeloma
TH
458
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31 e N685S, A688 V, A885 T, N898D K409 M e D605E e 1 I. C. PBSCT/
myelodysplastic
syndrome
TH
32 e N685S, A688 V, N898D K409 M e D605E e e I. C. Infantile spasm,
enterovirus
meningitis
TH
33 e N685S, A688 V, A885 T, N898D 668e680
deletion
e D605E e e I. C. AOM U
34 e N685S, A688 V, A885 T, N898D M828E
insertion
e e e 1 I. C. CMV hepatitis B
35 e N685S, A885 T, N898D M828E
insertion
e D605E e 2 I. C. ALL, CMV
pneumonitis
Sp
36 e A885 T, S897L, N898D e e e e e I. C. Lung cancer,
pneumonia
TH
37 e S655L, N685S, G874R, A885 T, N898D e e e e 1 I. C. sBMT/Beta-
thalassemia major
Sp
38 e N685S, A688 V, A885 T, N898D e e D605E E581A,
L583 W
1 I. C. ALL, pneumonia B
39 e N685S, A688 V, A885 T, N898D P642S, G672S e D605E e 4 I. C. Congenital CMV
infection
B
40 e N685S, A885 T, G874R, N898D T690A,
S694A
e e e 1 I. C. PBSCT/JMML Sp
a The known UL97 and UL54 GCV- resistance mutation were found.14,15
b Natural polymorphism among HCMV.16,17
c UL54 variations have not been reported previously.8,16
d The mutation D605E of UL97 is regarded as a natural polymorphism.18
e Sample source: outpatient clinic (O. C.)/inpatient clinic (I. C.)
f AIDS Z acquired immunodeficiency syndrome; ALL Z acute lymphoid leukemia; AOM Z acute otitis media; CBT Z cord d transplantation; DCM Z dilated cardiomyopathy;
JMMLZ juvenile myelomonocytic leukemia; OHTZ orthotopic heart transplantation; PBSCTZ peripheral blood stem cell trans ation; sBMTZ sibling bone marrow transplantation;
TOF Z tetralogy of Fallot; URI Z upper respiratory tract infection.
g aq. H Z aqueous humor; B Z blood; Sp Z sputum; TH Z throat swab; U Z urine.
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This is the first study to systemically examine the sequence
variation in UL54 and UL97 in cytomegalovirus strains in
Taiwan. Many mutations were found, but none of those
identified in the 40 samples were definitely associated with
ganciclovir resistance (see Table 1); most of them were
polymorphisms, including D605E in UL97 and the common
combination of N685S, A688V, A885T, N898D in UL54. These
polymorphisms were found in high frequency both in inpa-
tients and outpatient isolates. D605E in UL97 was commonly
found in our study. Although the UL97 mutation at codon
605 (D605E) was regarded as a natural variation or poly-
morphism,18 recent studies have revealed that double
mutations A594P/D605E and M460 V/D605E have conferred
ganciclovir resistance.19,20 We believe that the high
frequency of D605E variation might easily give rise to
ganciclovir-resistant HCMV in the future.
There were some unusual mutations, including nine in
UL54 (K409 M, A472 T, P642S, S646F, G672S, G678S, T690A,
S694A, and L957P) and six in UL97 (G391S, A477 V, L568 G,
E581A, L583 W, and A590 V).8,16 The frequency of these
mutations was 11/40 (28%) isolates in UL54 and 5/40 (13%) in
UL97. Notably, five of the nine (56%) patients who were
receiving ganciclovir harbored the unusual UL54mutations in
their HCMV isolates. In contrast, only six among 31 (19%)
patients without concurrent ganciclovir had mutations in
UL54, irrespective of their diagnosis. There were 2/9 (22%)
patients with ganciclovir treatment and 3/31 (10%) patients
without ganciclovir treatment who had unusual mutations in
UL97. The mutations in UL54 and UL97 seemed more
frequently found in the patients who were receiving ganci-
clovir. We could not infer what influence these mutations
might have had concerning resistance to ganciclovir without
using phenotypic analysis to calculate the 50% and 90%
inhibitory concentrations (IC50 and IC90) for ganciclovir.When
judging the possibility of ganciclovir resistance, the combi-
nation of genotypic and phenotypic analysis is necessary.13
A proportion of the HCMV strains tested were derived
from immunocompromised patients who may have been
taking antiviral drugs. We expected to detect resistance-
associated mutations in these HCMV strains but failed to
achieve that aim. Nevertheless, some polymorphisms and
unusual mutations were found in our study. Whether these
variations predispose HCMV isolated in Taiwan to drug
resistance needs further clarification. Therefore, contin-
uous monitoring of HCMV in Taiwan is needed to understand
the antiviral resistance status of the virus in Taiwan and to
guide its clinical management.
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